Incorporating patient-reported outcomes into hepatitis C virus treatment studies
- PMID: 24534544
- PMCID: PMC4104216
- DOI: 10.1016/j.cgh.2014.02.017
Incorporating patient-reported outcomes into hepatitis C virus treatment studies
Comment on
-
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. Clin Gastroenterol Hepatol. 2014. PMID: 24316172
References
-
- Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care. 2012;50(12):1060–1070. - PubMed
-
- Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2742–2751. - PubMed
-
- Younossi ZM, Stepanova M, Henry L, et al. Effects of Sofosbuvir-based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol. 2013 - PubMed
-
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
